Peripheral nerve blocks are widely used in regional anesthesia to provide postoperative analgesia while reducing opioid consumption and opioid-related side effects. The duration of analgesia with single-shot nerve blocks, however, is limited by the pharmacologic properties of local anesthetics. To prolong block duration and improve postoperative pain control, anesthesiologists frequently use adjuvant medications, with dexamethasone being among the most studied. Dexamethasone may be administered through either a perineural (adjacent to the targeted nerve) or intravenous (IV) route when used as an adjunct for peripheral nerve block. Considerable research has focused on determining whether one route offers superior analgesic outcomes.
Dexamethasone is a corticosteroid with potent anti-inflammatory and analgesic properties. Proposed mechanisms for prolonging nerve blockade include suppression of inflammatory mediators, reduction of ectopic neuronal discharge, and modulation of potassium channel activity in nociceptive fibers. Perineural administration was initially believed to exert a stronger local effect by acting directly at the nerve site. However, the observation that IV dexamethasone also prolongs block duration raised the possibility that systemic anti-inflammatory effects may account for much of the clinical benefit.
Numerous randomized controlled trials and meta-analyses have compared how perineural and IV dexamethasone administration extend the duration of peripheral nerve block. Most studies demonstrate that both routes significantly prolong sensory block duration and postoperative analgesia compared with placebo. However, perineural dexamethasone is generally reported to produce a longer duration of analgesia than IV administration, potentially lasting two to three hours longer. Other research suggests modest increases in sensory and motor block with the perineural route. In addition, some investigations have shown slightly lower postoperative pain scores and reduced opioid requirements.
Despite these findings, the clinical significance of the difference remains controversial. While the prolongation associated with perineural administration may reach statistical significance, many clinicians question whether a relatively small increase in analgesic duration meaningfully changes patient outcomes. Intravenous dexamethasone provides many of the same benefits without requiring off-label injection around peripheral nerves. IV administration also offers the added advantage of reducing postoperative nausea and vomiting, which may improve overall patient satisfaction and recovery.
Safety considerations continue to influence practice patterns. Current evidence has not demonstrated definitive neurotoxicity associated with perineural dexamethasone, and randomized trials have generally reported low complication rates. Nevertheless, concerns remain because long-term safety data are limited and perineural corticosteroid administration remains off-label in many countries. Some clinicians therefore favor IV dexamethasone because it avoids direct exposure of peripheral nerves to corticosteroids while still providing substantial analgesic prolongation.
Dose optimization of dexamethasone through these routes has also been studied extensively. Research suggests that both IV and perineural dexamethasone exhibit ceiling effects, meaning that increasing doses beyond a certain point does not have additional benefits on the peripheral nerve block. Most studies support the use of low-to-moderate doses to balance efficacy with minimization of systemic corticosteroid exposure. Variability in study design, local anesthetic selection, surgical procedures, and nerve block techniques has contributed to some inconsistency in the literature, but the overall evidence supports the effectiveness of both administration routes.
References
- Tan ESJ, Tan YR, Liu CWY. Efficacy of perineural versus intravenous dexamethasone in prolonging the duration of analgesia when administered with peripheral nerve blocks: a systematic review and meta-analysis. Korean J Anesthesiol. 2022;75(3):255-265.
- Baeriswyl M, Kirkham KR, Jacot-Guillarmod A, Albrecht E. Efficacy of perineural vs systemic dexamethasone to prolong analgesia after peripheral nerve block: a systematic review and meta-analysis. Br J Anaesth. 2017;119(2):183-191.
- Heesen M, Klimek M, Imberger G, et al. Co-administration of dexamethasone with peripheral nerve block: intravenous vs perineural application: systematic review, meta-analysis, meta-regression and trial-sequential analysis. Br J Anaesth. 2018;120(2):212-227.
- Chong MA, Berbenetz NM, Lin C, Singh S. Perineural versus intravenous dexamethasone as an adjuvant for peripheral nerve blocks: a systematic review and meta-analysis. Reg Anesth Pain Med. 2017;42(3):319-326.
- Zufferey PJ, Chaux R, Lachaud PA, et al. Dose-response relationships of intravenous and perineural dexamethasone as adjuvants to peripheral nerve blocks: a systematic review and model-based network meta-analysis. Br J Anaesth. 2024;132(5):1122-1132.